CN1030964C - 用于制备具有减少了苦味的阿扎利得组合物的方法 - Google Patents

用于制备具有减少了苦味的阿扎利得组合物的方法 Download PDF

Info

Publication number
CN1030964C
CN1030964C CN93109317A CN93109317A CN1030964C CN 1030964 C CN1030964 C CN 1030964C CN 93109317 A CN93109317 A CN 93109317A CN 93109317 A CN93109317 A CN 93109317A CN 1030964 C CN1030964 C CN 1030964C
Authority
CN
China
Prior art keywords
mycin
taste
bitterness
admixture
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93109317A
Other languages
English (en)
Chinese (zh)
Other versions
CN1083728A (zh
Inventor
J·S·卡塔尼亚
A·D·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1083728A publication Critical patent/CN1083728A/zh
Application granted granted Critical
Publication of CN1030964C publication Critical patent/CN1030964C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
CN93109317A 1992-07-30 1993-07-29 用于制备具有减少了苦味的阿扎利得组合物的方法 Expired - Fee Related CN1030964C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92226292A 1992-07-30 1992-07-30
US922,262 1992-07-30

Publications (2)

Publication Number Publication Date
CN1083728A CN1083728A (zh) 1994-03-16
CN1030964C true CN1030964C (zh) 1996-02-14

Family

ID=25446788

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93109317A Expired - Fee Related CN1030964C (zh) 1992-07-30 1993-07-29 用于制备具有减少了苦味的阿扎利得组合物的方法

Country Status (29)

Country Link
US (1) US5633006A (enExample)
EP (1) EP0582396B1 (enExample)
JP (1) JP2685403B2 (enExample)
KR (1) KR100242399B1 (enExample)
CN (1) CN1030964C (enExample)
AT (1) ATE198421T1 (enExample)
AU (1) AU655892B2 (enExample)
CA (1) CA2101466C (enExample)
CZ (1) CZ285057B6 (enExample)
DE (1) DE69329810T2 (enExample)
DK (1) DK0582396T3 (enExample)
EG (1) EG20385A (enExample)
ES (1) ES2153836T3 (enExample)
FI (1) FI933404A7 (enExample)
GR (1) GR3035426T3 (enExample)
HR (1) HRP931049B1 (enExample)
HU (1) HU221682B1 (enExample)
IL (1) IL106451A (enExample)
MX (1) MX9304577A (enExample)
MY (1) MY110581A (enExample)
NO (1) NO308023B1 (enExample)
NZ (1) NZ248280A (enExample)
PL (1) PL174795B1 (enExample)
PT (1) PT582396E (enExample)
RU (1) RU2126257C1 (enExample)
SK (1) SK280194B6 (enExample)
TW (1) TW271400B (enExample)
YU (1) YU52593A (enExample)
ZA (1) ZA935475B (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
JP3610418B2 (ja) * 1995-08-08 2005-01-12 カシオ計算機株式会社 液晶駆動方法及び液晶表示装置
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
GB9725219D0 (en) * 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
CA2362227A1 (en) * 1999-02-18 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Masking agent comprising salt of gluconic acid
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
JP2004537566A (ja) * 2001-08-01 2004-12-16 ブリストル−マイヤーズ　スクイブ　カンパニー 味マスキング組成物
EA200400214A1 (ru) * 2001-08-21 2004-06-24 Пфайзер Продактс Инк. Азитромицин в виде разовой дозы
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
KR100994032B1 (ko) * 2002-04-26 2010-11-11 니혼 텐사이 세이토 가부시키가이샤 마그네슘, 아연, 구리 흡수 촉진제
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
CA2521253A1 (en) * 2003-04-02 2004-10-14 Pliva Istrazivanje I Razvoj D.O.O. Pharmaceutical compositions having reduced bitter taste
KR100503949B1 (ko) * 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
EP1689368B1 (en) 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
ATE399536T1 (de) 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
EP1691786A1 (en) 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
US20060024335A1 (en) * 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
JP2006052169A (ja) * 2004-08-12 2006-02-23 Wakoudou Kk ゾル状又はゲル状の服薬補助食品
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2016202290B2 (en) * 2005-06-17 2017-10-05 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
JP4963846B2 (ja) * 2006-03-03 2012-06-27 エルメッド エーザイ株式会社 口腔内崩壊錠及びその製造方法
ES2355306T3 (es) * 2006-03-16 2011-03-24 Novartis Ag Forma de dosificación sólida que contiene un agente activo de sabor enmascarado.
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
EP2244699A2 (en) * 2008-01-31 2010-11-03 Mcneil-PPC, Inc Edible film-strips for immediate release of active ingredients
EP2098219A1 (en) * 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
WO2012029913A1 (ja) * 2010-09-01 2012-03-08 興和株式会社 経口剤
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US10092651B2 (en) * 2012-02-28 2018-10-09 Seoul Pharma Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN103961368B (zh) * 2013-12-05 2017-01-04 广西大学 蒙脱石负载的氢氧化钙抗酸剂
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) * 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JP7406349B2 (ja) * 2018-11-16 2023-12-27 エスエス製薬株式会社 イブプロフェン含有経口用医薬製剤
EP3973030A4 (en) * 2019-05-23 2023-05-31 Ekyj Consulting II, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT AND RELIEF OF ALCOHOLIC-INDUCED SKIN REMOVAL
US20240065303A1 (en) * 2020-12-22 2024-02-29 Solugen, Inc. Bitter masking agent
CN117119899A (zh) * 2021-04-28 2023-11-24 米卡·塔皮奥·雷约宁 能量饮料的组合物及其制造方法
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US4127645A (en) * 1976-05-21 1978-11-28 Life Savers, Inc. Effervescent tablet and method
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
US4761274A (en) * 1986-03-27 1988-08-02 Warner-Lambert Company Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
JP2831004B2 (ja) * 1988-09-29 1998-12-02 大日本製薬株式会社 粉粒状医薬製剤
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH05139996A (ja) * 1991-11-15 1993-06-08 Lion Corp 苦味が軽減された鎮咳去痰製剤用組成物
IL104093A (en) * 1991-12-31 1999-06-20 Abbott Lab Prolamine is expected to mask the taste of drugs given orally
JPH05255120A (ja) * 1992-03-12 1993-10-05 Taisho Pharmaceut Co Ltd 苦み隠蔽製剤
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
PL174795B1 (pl) 1998-09-30
CA2101466A1 (en) 1994-01-31
IL106451A (en) 1998-04-05
SK82193A3 (en) 1994-02-02
DE69329810T2 (de) 2001-06-21
JPH06206824A (ja) 1994-07-26
NZ248280A (en) 1995-07-26
MX9304577A (es) 1994-02-28
CN1083728A (zh) 1994-03-16
GR3035426T3 (en) 2001-05-31
NO932736D0 (no) 1993-07-29
HUT64692A (en) 1994-02-28
ATE198421T1 (de) 2001-01-15
RU2126257C1 (ru) 1999-02-20
DK0582396T3 (da) 2001-04-09
EP0582396B1 (en) 2001-01-03
FI933404L (fi) 1994-01-31
CZ151893A3 (en) 1994-03-16
NO308023B1 (no) 2000-07-10
HU221682B1 (hu) 2002-12-28
AU4426193A (en) 1994-04-28
NO932736L (no) 1994-01-31
SK280194B6 (sk) 1999-09-10
EP0582396A1 (en) 1994-02-09
KR940001902A (ko) 1994-02-16
PL299865A1 (en) 1994-02-07
MY110581A (en) 1998-08-29
IL106451A0 (en) 1993-11-15
HRP931049A2 (en) 1997-08-31
YU52593A (sh) 1996-05-20
US5633006A (en) 1997-05-27
HRP931049B1 (en) 2001-06-30
JP2685403B2 (ja) 1997-12-03
CA2101466C (en) 2000-06-06
FI933404A7 (fi) 1994-01-31
KR100242399B1 (ko) 2000-03-02
AU655892B2 (en) 1995-01-12
EG20385A (en) 1999-02-28
ZA935475B (en) 1995-01-29
TW271400B (enExample) 1996-03-01
PT582396E (pt) 2001-04-30
ES2153836T3 (es) 2001-03-16
HU9302213D0 (en) 1993-10-28
CZ285057B6 (cs) 1999-05-12
DE69329810D1 (de) 2001-02-08
FI933404A0 (fi) 1993-07-29

Similar Documents

Publication Publication Date Title
CN1030964C (zh) 用于制备具有减少了苦味的阿扎利得组合物的方法
DE60226012T2 (de) Geschmacksmaskierte pharmazeutische formulierungen
US20080181932A1 (en) Compositions for oral delivery of pharmaceuticals
AU2002302147B2 (en) Pharmaceutical composition
JPH10510817A (ja) チュアブル製剤
EP1372662A1 (en) Taste masked liquid pharmaceutical compositions
WO1993012771A1 (en) Prolamine coatings for taste-masking orally-administrable medicaments
WO2004000281A1 (en) Rapidly disintegrating tablet
JP4384278B2 (ja) イブプロフェン含有粒剤
US20030108605A1 (en) Mineral supplement
CN101491677A (zh) 一种制备减轻了苦味药剂组合物的方法
KR20030027422A (ko) 쓴맛의 은폐효과가 우수한 세푸록심 아세틸 약제 조성물과그 제조방법

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee